Matrix Pharmaceutical Completes Enrollment in IntraDose Clinical Trials

Strategic Insights -

Matrix Pharmaceutical, Inc. announced the completion of enrollment in both United States and European clinical trials of IntraDose(TM) (cisplatin/epinephrine) Injectable Gel for the treatment of solid tumors. These trials are companion studies to Phase III registration-directed trials of IntraDose in patients with advanced head and neck cancer. The company will present safety and efficacy data from these studies at several Fall 1998 medical meetings.

Key Takeaways:

  • Matrix Pharmaceutical has completed enrollment in both United States and European clinical trials of IntraDose(TM) (cisplatin/epinephrine) Injectable Gel for the treatment of solid tumors.
  • The IntraDose solid tumor trials are companion studies to Phase III registration-directed trials of IntraDose in patients with advanced head and neck cancer.
  • Enrollment in the head and neck studies is projected to be completed next year, with a total of 127 patients having been enrolled in the IntraDose solid tumor studies.
  • The company will present safety and efficacy data from these studies at several Fall 1998 medical meetings, including the Radiological Society of North America.
  • IntraDose Injectable Gel is in Phase III studies for the treatment of head and neck cancer and other solid tumors.
  • Matrix Pharmaceutical's Radiopotentiator MPI 5020 will be the subject of presentations at the European Society for Therapeutic Radiology and Oncology and the American Society for Therapeutic Radiology and Oncology.
  • The company's Senior Vice President, Medical and Regulatory Affairs, stated that the completion of enrollment in the two IntraDose studies is a significant accomplishment, expanding the experience with IntraDose in various solid tumors in addition to head and neck cancer.

Statistics:

  • A total of 127 patients have been enrolled in the IntraDose solid tumor studies to date.
  • The IntraDose solid tumor trials are companion studies to Phase III registration-directed trials of IntraDose in patients with advanced head and neck cancer.
  • Enrollment in the head and neck studies is projected to be completed next year.
  • The company will present safety and efficacy data from these studies at several Fall 1998 medical meetings.

Sources:

  • Business Wire, "Matrix Pharmaceutical, Inc. Completes Enrollment in IntraDose(TM) Clinical Trials," September 14, 1998.
  • Matrix Pharmaceutical Inc.'s press release, "Matrix Pharmaceutical Completes Enrollment in IntraDose(TM) Clinical Trials," September 14, 1998.